Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clovis Oncology, Inc. - Common Stock (NQ:CLVS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clovis Oncology, Inc. - Common Stock

< Previous 1 2 Next >
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
From Clovis Oncology, Inc.
Via Business Wire
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
From Clovis Oncology, Inc.
Via Business Wire
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
Via FinancialNewsMedia
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces Second Quarter 2021 Operating Results
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
From Clovis Oncology, Inc.
Via Business Wire
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
From Clovis Oncology, Inc.
Via Business Wire
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces At-The-Market Equity Offering Program
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces First Quarter 2021 Operating Results
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology to Present at the Bank of America 2021 Health Care Conference
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
From Clovis Oncology, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.